deltatrials
Completed PHASE2 NCT00002792

Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders

ALLOGENEIC MARROW OR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR AGNOGENIC MYELOID METAPLASIA WITH MYELOFIBROSIS

Sponsor: Fred Hutchinson Cancer Center

Conditions Chronic Myeloproliferative Disorders Leukemia Myelodysplastic/Myeloproliferative Diseases
Interventions allogeneic bone marrow transplantation busulfan cyclophosphamide cyclosporine methotrexate peripheral blood stem cell transplantation tacrolimus
Updated 6 times since 2017 Last updated: Mar 31, 2010 Started: Jun 30, 1996 Primary completion: Apr 30, 2003 Completion: Apr 30, 2003

Listed as NCT00002792, this PHASE2 trial focuses on Chronic Myeloproliferative Disorders and Leukemia and remains completed. Sponsored by Fred Hutchinson Cancer Center, it has been updated 6 times since 1996, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. May 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — May 2022 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Jun 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fred Hutchinson Cancer Center
  • National Cancer Institute (NCI)
Data source: Fred Hutchinson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Seattle, United States